Analysts Expect DexCom, Inc. (DXCM) to Announce $0.14 EPS

Equities research analysts predict that DexCom, Inc. (NASDAQ:DXCM) will announce earnings of $0.14 per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for DexCom’s earnings, with the highest EPS estimate coming in at $0.22 and the lowest estimate coming in at $0.09. DexCom posted earnings per share of $0.10 during the same quarter last year, which would indicate a positive year over year growth rate of 40%. The business is expected to report its next quarterly earnings report on Tuesday, February 26th.

According to Zacks, analysts expect that DexCom will report full year earnings of ($0.12) per share for the current fiscal year, with EPS estimates ranging from ($0.19) to ($0.08). For the next financial year, analysts expect that the company will report earnings of $0.24 per share, with EPS estimates ranging from $0.05 to $0.40. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for DexCom.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.29. The company had revenue of $266.70 million for the quarter, compared to analysts’ expectations of $242.72 million. DexCom had a negative return on equity of 2.89% and a net margin of 4.72%. DexCom’s quarterly revenue was up 44.5% on a year-over-year basis.

DXCM has been the topic of a number of research reports. BidaskClub cut DexCom from a “buy” rating to a “hold” rating in a report on Wednesday, October 3rd. Morgan Stanley raised their price objective on DexCom from $130.00 to $150.00 and gave the company an “equal weight” rating in a report on Thursday, October 11th. Goldman Sachs Group raised DexCom from a “sell” rating to a “neutral” rating and set a $125.00 price objective on the stock in a report on Friday, October 19th. Raymond James raised their price objective on DexCom from $125.00 to $150.00 and gave the company an “outperform” rating in a report on Tuesday, October 23rd. Finally, Oppenheimer set a $150.00 price objective on DexCom and gave the company a “buy” rating in a report on Wednesday, November 7th. Seven analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. DexCom presently has an average rating of “Buy” and a consensus target price of $143.53.

Shares of NASDAQ DXCM traded up $0.98 during trading hours on Thursday, reaching $150.50. 27,526 shares of the stock traded hands, compared to its average volume of 1,114,766. The stock has a market cap of $13.28 billion, a price-to-earnings ratio of -258.62 and a beta of 0.63. The company has a current ratio of 4.71, a quick ratio of 4.43 and a debt-to-equity ratio of 0.60. DexCom has a 52-week low of $52.92 and a 52-week high of $152.69.

In related news, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, January 14th. The stock was sold at an average price of $140.99, for a total transaction of $845,940.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Heather S. Ace sold 4,258 shares of the firm’s stock in a transaction that occurred on Friday, November 9th. The stock was sold at an average price of $147.32, for a total value of $627,288.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,912 shares of company stock worth $9,823,547. 1.80% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of DXCM. First Hawaiian Bank grew its position in shares of DexCom by 75.6% in the 4th quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock worth $47,000 after buying an additional 170 shares during the last quarter. JS Capital Management LLC bought a new stake in shares of DexCom in the 3rd quarter worth approximately $100,000. Stratos Wealth Partners LTD. bought a new stake in shares of DexCom in the 3rd quarter worth approximately $124,000. IBM Retirement Fund bought a new stake in shares of DexCom in the 3rd quarter worth approximately $203,000. Finally, HPM Partners LLC bought a new stake in shares of DexCom in the 3rd quarter worth approximately $203,000. Institutional investors and hedge funds own 99.15% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: What are no-load funds?

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply